This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Warren, J. S. Articles by Neidhart, J. A. Search for Related Content PubMed PubMed Citation Articles by Warren, J. S. Articles by Neidhart, J. A.

Lysozyme Enhancement of Tumor Cell Immunoprotection in a Murine Fibrosarcoma¹

Division of Hematology-Oncology, Department of Medicine [J. S. W., J. J. R., J. A. N.], and Department of Microbiology [B. S. Z.], The Ohio State University, Columbus, Ohio 43210

We examined the ability of human lysozyme (HLZM) to enhance the immunogenicity of a methylcholanthrene-induced murine fibrosarcoma in C57BL/10 mice. Following s.c. injection of 10⁴ live tumor cells, 100% of mice developed palpable tumors within 16 ± 3 (S.D.) days. Prechallenge immunization with 10⁶ irradiated tumor cells with or without complete Freund's adjuvant resulted in protection from tumor development in 14 and 22% of mice, respectively. Incubation of tumor cells with HLZM prior to immunization approximately doubled the degree of protection, with 42 to 44% of mice remaining free of tumor. This enhanced protection was dependent on the enzymatic activity of HLZM. These data suggest that HLZM enhances tumor cell immunogenicity in this model.

¹ Supported in part by a gift from Dr. and Mrs. Herbert Fenbur and NIH Grants R01-CA-26286-01 and CA-15147-07.

² To whom requests for reprints should be addressed, at The Ohio State University Hospitals, 410 West Tenth Avenue, Room N-1022, Columbus, Ohio 43210.

Received 8/12/80. Accepted 1/20/81.